Results 251 to 260 of about 276,970 (298)

Influence of Residual Disease on the Efficacy of PARP Inhibitors in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta Analysis. [PDF]

Cancers (Basel)
Hwang S, Kim JH, Kim U, Ha HI, Park SY, Lim MC.   +5 more
europepmc   +1 more source

High-Mannose <i>N</i>-Glycans To Monitor Early Response to Chemotherapy in African Epithelial Ovarian Cancer Patients─A Pilot Study. [PDF]

J Proteome Res
Wanyama FM, Umeh O, Biskup K, Tauber R, Mokomba A, Nyongesa C, Blanchard V.   +6 more
europepmc   +1 more source

Identification of novel biomarkers for epithelial ovarian cancer through machine learning and explainable artificial intelligence using in silico and in vitro analysis. [PDF]

Sci Rep
Chekini Z, Dehghani T, Khayami R, Jafarian AH, Farazestanian M, Hassanzadeh M, Pasdar A.   +6 more
europepmc   +1 more source

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Petousis S, Kahramanoglu I, Appenzeller-Herzog C, Angeles MA, Margioula-Siarkou C, Kacperczyk-Bartnik J, Bilir E, Chatzakis C, Caruso G, Bizzarri N, Dinas K, Bowtell DDL, Garsed DW, Ray-Coquard I, Ledermann JA, Friedlander M, Sotiriadis A, Heinzelmann-Schwarz V, Zwimpfer TA.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Alcohol and epithelial ovarian cancer

Journal of Clinical Epidemiology, 1992
The relationship between alcohol consumption and the risk of epithelial ovarian cancer was analysed using data from a case-control study of 801 histologically confirmed epithelial ovarian cancers and 2114 controls in hospital for acute, non-neoplastic, gynecological, or hormone-related conditions, admitted to a network of teaching and general hospitals
C. La Vecchia, E. Negri, S. Franceschi, F. Parazzini, A. Gentile, M. Fasoli   +5 more
openaire   +2 more sources

Epithelial Ovarian Cancer

Therapeutische Umschau. Revue therapeutique, 2007
Ovarian cancer (OC) is associated with the highest cancer-related mortality among gynecological cancers, since nearly 2/3 of patients are diagnosed with advanced stage disease which is caused by an unspecific clinical appearance and the lack of effective early detection methods.
F, Hilpert, G, Krause, L, Venhoff, E, Kühnle, C, Schem, N, Maass   +5 more
openaire   +3 more sources

Epithelial ovarian cancer

Current Treatment Options in Oncology, 2002
Epithelial ovarian cancer is the most lethal of all gynecologic malignancies. Most women have advanced stage disease. Access to appropriate initial surgical management by a gynecologic oncologist is important because treatment and survival are affected by appropriate surgical staging and debulking of tumor. After debulking/staging surgery, chemotherapy
openaire   +3 more sources

Prevention of Epithelial Ovarian Cancer

Cold Spring Harbor Perspectives in Medicine, 2023
Given the challenges with achieving effective and durable treatment for epithelial ovarian cancer, primary prevention is highly desirable. Fortunately, decades of research have provided evidence for several strategies that can be deployed to optimize risk reduction. These include surgery, chemoprevention, and lifestyle factor modifications. These broad
Thomas A, Sellers, Lauren C, Peres, Cassandra A, Hathaway, Shelley S, Tworoger   +3 more
openaire   +2 more sources

PATHOLOGY OF EPITHELIAL OVARIAN CANCER

Obstetrics and Gynecology Clinics of North America, 1994
Ovarian epithelial tumors can be benign, LMP, and malignant. The prognoses of these three types of tumors are entirely different. A frozen section has to be done on all ovarian tumors to determine if they are benign. All lesions that are LMP or malignant have to be surgically and pathologically staged.
C, Tornos, E G, Silva
openaire   +2 more sources